Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Jul 2017 Planned initiation date changed from 30 May 2017 to 1 Jul 2017.
- 04 May 2017 New trial record